A phase IIa randomized clinical trial with therapeutic application of HspB5 in relapsing-remitting multiple sclerosis patients, using intravenous doses of HspB5 was completed in 2015. This evidence concerns the gene CRYAB and relapsing-remitting multiple sclerosis.